Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04307407
Other study ID # 2019/1318
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 8, 2020
Est. completion date March 2, 2023

Study information

Verified date March 2023
Source Norwegian School of Sport Sciences
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to compare the effects of aerobic exercise to usual care in women treated with chemotherapy and radiation therapy for non-metastatic breast cancer


Description:

In this study, we will compare the effects of exercise between women previously treated with breast cancer to women with no history of any cancers. Therefore, in addition to a randomized controlled trial in women with previous breast cancer (i.e., an exerciser group and a control group), we also include a reference group comprising age-matched women with no history of any cancer diagnosis. Women in the reference group will undergo a similar exercise intervention and the exercise group. This study recruits through invitation only. The primary endpoint in this study is the change in cardiorespiratory fitness, measured as VO2peak. Secondary endpoints include common risk factors for cardiovascular disease and cardiometabolic health, endpoints derived from the cardiopulmonary exercise test and lung function assessments, cellular muscle endpoints derived from muscle biopsies obtained from m. vastus lateralis, also patient-reported outcomes.


Recruitment information / eligibility

Status Completed
Enrollment 210
Est. completion date March 2, 2023
Est. primary completion date March 2, 2023
Accepts healthy volunteers No
Gender Female
Age group 28 Years to 72 Years
Eligibility Inclusion Criteria: - Eligible BCS must be listed in the Norwegian Cancer registry - Female - Adult-onset breast cancer diagnosis, diagnosed between 2008 and 2012 - 60 years or younger at the time of diagnosis - received anthracycline-based chemotherapy as a part of their treatment history - signed informed consent and medical doctors approveal of participation prior to inclusion Exclusion Criteria: - Received Herceptin - Diagnosed with stage IV breast cancer - Relapse since diagnosis - A history, or current presence, of another diagnosis of invasive cancer of any kind - Selfreported severe fatigue - present with any uncontrolled- or recent cardiovascular disease, has undergone heart surgery or uses a pacemaker - currently exercising more than 90 minutes per week

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Aerobic Exercise
Participants will be randomized to supervised aerobic exercise or standard care. Women with no current or past malignant disease will comprise the reference group and will be matched for age to participants in the Aerobic Exercise arm

Locations

Country Name City State
Norway Norwegian School of Sport Sciences Oslo

Sponsors (4)

Lead Sponsor Collaborator
Norwegian School of Sport Sciences Memorial Sloan Kettering Cancer Center, Oslo University Hospital, University of Oslo

Country where clinical trial is conducted

Norway, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in VO2peak Peak oxygen uptake during a treadmill based cardiopulmonary exercise test From baseline to five months (post-intervention)
Secondary Systolic- and diastolic heart chamber dimensions Cardiac morphology and function will be assessed by 2D and 3D Echocardiography and 2D strain echocardiography From baseline to five months (post-intervention)
Secondary Systolic- and diastolic longitudinal strain Cardiac morphology and function will be assessed by 2D and 3D Echocardiography and 2D strain echocardiography From baseline to five months (post-intervention)
Secondary Lean body mass Body composition will be assessed by dual x-ray absorptiometry From baseline to five months (post-intervention)
Secondary Fat mass Body composition will be assessed by dual x-ray absorptiometry From baseline to five months (post-intervention)
Secondary Blood volume Hemoglobin mass and blood volume will be assessed using the carbon monoxide rebreathing method From baseline to five months (post-intervention)
Secondary Muscle fiber type Change in muscle morphology will be assessed in muscle biopsies using immunohistochemistry From baseline to five months (post-intervention)
Secondary Muscle fiber area Change in muscle morphology will be assessed in muscle biopsies using immunohistochemistry From baseline to five months (post-intervention)
Secondary Muscle mitochondria mass Change in mitochondrial proteins will be assessed in muscle biopsies using western blot From baseline to five months (post-intervention)
Secondary Quality of life: Quality of Life Questionnaire (QLQ) C-30 Relevant patient reported outcomes will be obtained using validated Quality of Life Questionnaire (QLQ) C-30 From baseline to five months (post-intervention)
Secondary Genome-wide DNA methylation and gene expression For a sub-group of participants, muscle biopsies will be further processed for RNA and DNA From baseline to five months (post-intervention)
See also
  Status Clinical Trial Phase
Recruiting NCT04681911 - Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer Phase 2
Terminated NCT04066790 - Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer Phase 2
Completed NCT04890327 - Web-based Family History Tool N/A
Completed NCT03591848 - Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility N/A
Recruiting NCT03954197 - Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients N/A
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Active, not recruiting NCT01472094 - The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
Completed NCT06049446 - Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
Withdrawn NCT06057636 - Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study N/A
Recruiting NCT05560334 - A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations Phase 2
Active, not recruiting NCT05501769 - ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer Phase 1
Recruiting NCT04631835 - Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer Phase 1
Recruiting NCT03544762 - Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation Phase 3
Terminated NCT02482389 - Study of Preoperative Boost Radiotherapy N/A
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Completed NCT00226967 - Stress, Diurnal Cortisol, and Breast Cancer Survival
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT06019325 - Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy N/A
Recruiting NCT05622240 - 99mTc-MIRC213 SPECT/CT for the Detection of HER2-positive Breast Cancer Early Phase 1